Quick Takeaways
- Vivo Capital IX, LLC filed SCHEDULE 13D/A for Sinovac Biotech Ltd. Common Shares, $0.001 par value per share (SVA).
- Disclosed ownership: 6.3%.
- Date of event: 17 Mar 2025.
Vivo Capital IX, LLC - 17 Mar 2025 SCHEDULE 13D/A Report for Sinovac Biotech Ltd. Common Shares, $0.001 par value per share (SVA)
- Filing Manager
- Vivo Capital IX, LLC
- Reporting Manager
- Vivo Capital IX, LLC
- Symbol
- SVA
- Shares outstanding
- 72,054,857 shares
- Disclosed Ownership
- 4,539,456 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13D/A
- Filing time
- 19 Mar 2025, 15:00:38 UTC
- Date of event
- 17 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vivo Capital IX, LLC disclosed 6.3% ownership in Sinovac Biotech Ltd. Common Shares, $0.001 par value per share (SVA) on 17 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 19 Mar 2025, 15:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vivo Capital VIII, LLC | 1.9% | 1,360,544 | 0 | 1,360,544 | /s/ Dr. Frank Kung | Dr. Frank Kung, Managing Member | 0001618789 |
| Vivo Capital IX, LLC | 6.3% | 4,539,456 | 0 | 4,539,456 | /s/ Dr. Frank Kung | Dr. Frank Kung, Managing Member | 0001750698 |